



2026 World Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA

ARIAN, a Phase III, Randomized Study of Adjuvant Treatment With Sacituzumab And Zimberelimab In Resected Patients

Virginia Calvo, Rafael López Castro, Clara Lucía Gozálviz, David Aguiar, Amelia Insa, Manuel Dómine, Manuel Fernandez Bruno, Oscar Juan-Vidal, Bartomeu Massutí, Alejandro Olivares, M. Carmen Areses, Aitor Azkárte, Soledad Medina, Marta Domènech, Javier-David Benitez-Fuentes, Reyes Bernabé, Karla Medina, Noemi Reguart, M. Angeles Moreno, Begoña Campos, Mónica Antoñanzas, Andrés Barba, Remei Blanco, Juan Coves, Javier de Castro, Martin Lázaro, Alex Martínez-Marti, Ernest Nadal, M. Angeles Sala2, Laia Vila, Joaquin Gimeno, Silvia Sequero, Mariano Provencio on behalf of the Spanish Lung Cancer Group (Fundación GECP).

- Spain -

Disclosure

Employment

Medical Oncologist, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Research Grants

None

Consultant

Roche, AstraZeneca, MSD, BMS, Takeda, Regeneron, Amgen, Pfizer, GSK, Boehringer Ingelheim, Johnson & Johnson, BeOne Medicines

Stock holder

None.

Disclosure

Artificial Intelligence (AI) Use Disclaimer

In accordance with the standards and guidance set forth by the Accreditation Council for Continuing Medical Education (ACCME), individuals in control of content are required to disclose the use of artificial intelligence (AI) in the development of educational materials. This includes identification of the specific AI tool(s) utilized and a description of how AI contributed to content creation as a slide reference.


No AI tools were used in the preparation of this presentation.

Background

- Pathological complete response (pCR) is associated with improved outcomes, including reductions in risk of recurrence, longer event-free intervals and lower mortality¹.
- Immunotherapy targeting PD-1/PD-L1 has improved survival outcomes and pCR rates in resectable disease².
- Despite advances in major perioperative chemoimmunotherapy trials, only around 17-37% of patients achieved pCR³⁻⁵.
- The combination of PD-1/PD-L1 agents and antibody-drug conjugates (ADCs), such as the TROP-2 directed-ADC sacituzumab govitecan (SG), represent a promising therapeutic option in clinical practice⁶.
- The ARIAN trial (NCT06431633) was designed to evaluate the combination of SG and zimberelimab in patients with resected NSCLC who failed to achieve pCR following neoadjuvant chemo-immunotherapy.

¹Li C, et al. Int J Surg. 2025; ²Provencio M, et al. Lancet. 2025; ³Provencio M, et al. N Engl J Med. 2023; ⁴Forde PM, et al. J Clin Oncol. 2008; ⁵Heymach JV, et al. N Engl J Med. 2023; ⁶Bessede A, et al. Clin Cancer Res. 2024


Clinical Need



ARIAN evaluates for the first time adjuvant therapy in resected NSCLC patients with residual viable tumor after neoadjuvant chemoimmunotherapy.

Study Design

Phase III, multicenter, open-label, randomized trial



Abbreviation: **CT:** Computed tomography; **CTCAE:** Common Terminology Criteria for Adverse Events; **ctDNA:** circulating tumor DNA; **ECOG PS:** Eastern Cooperative Oncology Group performance status; **IASLC:** International Association for the Study of Lung Cancer; **EOT:** end of treatment; **NSCLC:** Non-small cell lung cancer; **MRI:** Magnetic resonance imaging; **Q3W:** every 3 weeks; **R0 resection:** complete resection; **PD-L1:** programmed death receptor-ligand 1; **PET:** Positron emission tomography. Abbreviation: **CT:** Computed tomography; **CTCAE:** Common Terminology Criteria for Adverse Events; **ctDNA:** circulating tumor DNA; **ECOG PS:** Eastern Cooperative Oncology Group performance

Recruitment Status (June 2026)



30
sites



August 2024
Study approval



129
Planned
enrollment



47
Screened



31
Enrolled

Treatment allocation




Conclusions

- **ARIAN is an innovative study in perioperative NSCLC**, addressing a key unmet question that prior adjuvant and neoadjuvant trials were not designed to answer.
- **Biological rationale:** TROP2 directed ADC plus PD-1 blockade may help eliminate residual disease and reverse immune escape in the adjuvant setting.
- If positive, **ARIAN could reshape adjuvant NSCLC management**, supporting postoperative treatment in patients without pCR, and impact future guideline recommendations.

Acknowledgments

We would like to thank the patients and their families, and all the participating trial investigators. The study is funded by Gilead Sciences and sponsored by the Spanish Lung Cancer Group (Fundación GECRP).

감사합니다



Gracias

Thank You.